Breaking News

Kerry Says Mideast Cease-Fire Talks to Continue Tomorrow
Tweet TWEET

Accelerate Diagnostics, Inc. Names Mark C. Miller to Board of Directors

   Accelerate Diagnostics, Inc. Names Mark C. Miller to Board of Directors

PR Newswire

TUCSON, Ariz., Nov. 6, 2013

TUCSON, Ariz., Nov. 6, 2013 /PRNewswire/ --Accelerate Diagnostics, Inc.
(NASDAQ: AXDX), an in vitro diagnostics company dedicated to providing
solutions for the global challenge of drug resistant organisms and hospital
acquired infections, announced today that Mark C. Miller has been appointed to
its Board of Directors.

Mr. Millercurrently serves as Executive Chairman and director of Stericycle
(NASDAQ: SRCL) where he was Chief Executive Officer from 1992 to 2012 and
Chairman of the Board of Directors from 2008 to 2012. During his 20 years as
CEO, Mark grew Stericycle's revenues from $1.6 million to $1.9 billion, and in
2009 was selected by Morningstar, Inc. as its "CEO of the Year." Prior to
joining Stericycle, Mr. Miller served as vice president for the Pacific, Asia
and Africa in the international division of Abbott Laboratories, a diversified
health care company, which he joined in 1976 and where he held a number of
management and marketing positions. Mr. Miller formerly served as a director
of Ventana Medical Systems, Inc., a developer and supplier of automated
diagnostic systems. He received a B.S. degree in computer science from Purdue
University, where he graduated Phi Beta Kappa.

"We are pleased to have Mark join our Board. His leadership, expertise and
wisdom were crucial to the tremendous success of Stericycle. We are looking
forward to him applying these skills at Accelerate Diagnostics," commented
John Patience, Accelerate Diagnostic's Chairman.

ABOUT ACCELERATE DIAGNOSTICS

Accelerate Diagnostics, Inc. (NASDAQ: AXDX) is an in vitro diagnostics company
dedicated to providing solutions for the global challenge of drug resistant
organisms and hospital acquired infections. We are focused on developing and
commercializing innovative instrumentation for the rapid identification and
antibiotic susceptibility testing of infectious pathogens. The Company's
revolutionary BACcel™ platform utilizes a proprietary culture-free process
with both genomic and phenotypic detection technologies that significantly
decreases time to result while achieving high sensitivity and specificity.

In addition to the BACcel system development pipeline, Accelerate Diagnostics
also owns and licenses its propriety OptiChem® surface coatings technology,
which has numerous applications for binding in bio-analytical systems, such as
microarrays.

SAFE HARBOR STATEMENT

Certain statements in this news release may be "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended. Statements
regarding future prospects and developments are based upon current
expectations and involve certain risks and uncertainties that could cause
actual results and developments to differ materially from the forward-looking
statement, including those detailed in the company's filings with the
Securities and Exchange Commission. Accelr8 does not undertake an obligation
to publicly update or revise any forward-looking statements, whether as a
result of new information or future events



SOURCE Accelerate Diagnostics, Inc.

Contact: Accelerate Diagnostics, Inc., Steve Reichling, CFO, (520) 365-3100